Although it sounds like an oxymoron, high-growth prospect dividend aristocrat stocks exist, although their industries may ...

The Inflation Reduction Act (IRA) authorized the federal government to force prescription drug manufacturers to "negotiate" drug prices for ...

PWV offers a concentrated, defensive value strategy, heavily weighted in financials and energy. Click here to read why PWV ...

In today's video, I will cover four of my favorite dividend stocks for the next five years, one of those being Broadcom (NASDAQ: AVGO). Where to invest $1,000 right now? Our analyst team just revealed ...

The promising results, along with a separate FDA decision, could signal a major expansion of the use of the two companies' ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

Abbvie's stock rises 4.51% despite looming trade tensions and competitive pressures. Analysts from Morgan Stanley, Raymond ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

AbbVie’s Skyrizi tallied the most TV impressions among pharma brands in July, rising from second in June. The psoriasis treatment achieved a share of voice (SOV) of 4.61% with 2.5 billion impressions.

Genmab and AbbVie are taking key steps toward moving their blood cancer drug Epkinly into earlier lines of treatment in ...

REGENXBIO to initiate pivotal phase IIb/III clinical trial of surabgene lomparvovec in diabetic retinopathy: Rockville, Maryland Friday, August 8, 2025, 15:00 Hrs [IST] REGENXBIO ...